Exponent, Inc. (NASDAQ:EXPO – Get Free Report) CEO Catherine Corrigan sold 1,707 shares of the company’s stock in a transaction on Monday, August 17th. The shares were sold at an average price of $66.28, for a total value of $113,139.96. Following the sale, the chief executive officer owned 129,108 shares of the company’s stock, valued at approximately $8,557,278.24. This trade represents a 1.30% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Catherine Corrigan also recently made the following trade(s):
- On Monday, June 15th, Catherine Corrigan sold 4,119 shares of Exponent stock. The stock was sold at an average price of $57.13, for a total value of $235,318.47.
Exponent Stock Up 2.0%
Shares of Exponent stock traded up $1.32 during trading hours on Tuesday, reaching $67.51. 380,459 shares of the stock traded hands, compared to its average volume of 537,623. The company has a 50 day moving average price of $62.15 and a 200 day moving average price of $64.59. The firm has a market capitalization of $3.21 billion, a price-to-earnings ratio of 30.27 and a beta of 0.68. Exponent, Inc. has a one year low of $51.91 and a one year high of $81.95.
Exponent Dividend Announcement
The firm also recently announced a quarterly dividend, which will be paid on Friday, September 18th. Shareholders of record on Friday, September 4th will be issued a dividend of $0.31 per share. This represents a $1.24 dividend on an annualized basis and a yield of 1.8%. The ex-dividend date of this dividend is Friday, September 4th. Exponent’s dividend payout ratio is currently 55.61%.
Analyst Ratings Changes
EXPO has been the topic of several analyst reports. UBS Group set a $72.00 price target on shares of Exponent and gave the stock a “neutral” rating in a research note on Friday, July 31st. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Exponent in a report on Friday, July 17th. Finally, JPMorgan Chase & Co. lifted their target price on Exponent from $80.00 to $90.00 and gave the company an “overweight” rating in a research report on Friday, July 31st. Two equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $81.00.
Get Our Latest Stock Analysis on EXPO
Institutional Investors Weigh In On Exponent
Several hedge funds and other institutional investors have recently added to or reduced their stakes in EXPO. Bell Investment Advisors Inc lifted its holdings in Exponent by 423.6% during the first quarter. Bell Investment Advisors Inc now owns 377 shares of the business services provider’s stock valued at $25,000 after purchasing an additional 305 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. bought a new stake in shares of Exponent during the 2nd quarter valued at $26,000. Allworth Financial LP raised its position in shares of Exponent by 86.1% during the 4th quarter. Allworth Financial LP now owns 469 shares of the business services provider’s stock valued at $33,000 after purchasing an additional 217 shares during the period. Public Employees Retirement System of Ohio purchased a new position in shares of Exponent during the 2nd quarter valued at $29,000. Finally, Bessemer Group Inc. lifted its stake in shares of Exponent by 37.1% during the 1st quarter. Bessemer Group Inc. now owns 717 shares of the business services provider’s stock valued at $47,000 after buying an additional 194 shares in the last quarter. 92.37% of the stock is owned by hedge funds and other institutional investors.
Exponent Company Profile
Exponent, Inc (NASDAQ: EXPO) is an engineering and scientific consulting firm that offers multidisciplinary analysis and advisory services to clients across a range of industries. The company’s expertise spans mechanical, materials and corrosion engineering, civil and structural engineering, electrical engineering, industrial hygiene, toxicology and health sciences, and failure analysis. Exponent provides support for product design, performance evaluation, litigation consulting, and regulatory compliance, helping manufacturers, insurers, law firms and government agencies address complex technical challenges.
Founded in 1967 in Menlo Park, California, Exponent has grown from a small failure-analysis laboratory into a global consulting practice.
Recommended Stories
- Five stocks we like better than Exponent
- The AI Boom Is Turning This Cable Maker Into a Stock to Watch
- A Star Investor Just Trimmed Amazon—Here’s What It means
- Wendy’s Deal Buzz May Give Fast-Food Investors a New Reason to Look
- Home Depot Analysts See a Path to $375 and Beyond
Receive News & Ratings for Exponent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exponent and related companies with MarketBeat.com's FREE daily email newsletter.
